1. Witt M, Meier J, Hammitzsch A, Proft F, Schulze-Koops H, Grunke M. Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: results from a nationwide patient survey. Semin Arthritis Rheum. 2014; 43:745–50.
Article
2. Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME. The SAPHO syndrome. Semin Arthritis Rheum. 2012; 42:254–65.
Article
3. Kramer SC, Thomas CJ, Tyler WB, Elston DM. Kaposi's varicelliform eruption: a case report and review of the literature. Cutis. 2004; 73:115–22.
4. Assmann G, Kueck O, Kirchhoff T, Rosenthal H, Voswinkel J, Pfreundschuh M, et al. Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an inter-ventional study. Arthritis Res Ther. 2009; 11:R140.
Article
5. Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res. 1995; 12:916–22.
6. Colina M, La Corte R, Trotta F. Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol. 2009; 27:112–5.
7. Green JR. Antitumor effects of bisphosphonates. Cancer. 2003; 97(3 Suppl):840–7.
Article
8. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford). 2004; 43:658–61.
Article
9. Fioravanti A, Cantarini L, Burroni L, Mazzei MA, Volterrani L, Galeazzi M. Efficacy of alendronate in the treatment of the SAPHO syndrome. J Clin Rheumatol. 2008; 14:183–4.
Article
10. Ichikawa J, Sato E, Haro H, Ando T, Maekawa S, Hamada Y. Successful treatment of SAPHO syndrome with an oral bisphosphonate. Rheumatol Int. 2009; 29:713–5.
Article
11. Song X, Sun W, Meng Z, Gong L, Tan J, Jia Q, et al. Diagnosis and treatment of SAPHO syndrome: a case report. Exp Ther Med. 2014; 8:419–22.
Article